{"id":"tocilizumab-roactemra-actemra","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Infection (including serious infections)"},{"rate":"10-15","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"10-15","effect":"Hyperlipidemia"},{"rate":"5-10","effect":"Neutropenia"},{"rate":"5-8","effect":"Headache"},{"rate":"5-8","effect":"Hypertension"},{"rate":"<1","effect":"Gastrointestinal perforation (rare)"}]},"_chembl":{"chemblId":"CHEMBL1237022","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-6 is a key cytokine in inflammatory and autoimmune diseases. By binding to both membrane-bound and soluble IL-6 receptors, tocilizumab prevents IL-6 from activating immune cells and promoting inflammation. This reduces the production of other inflammatory mediators and helps suppress the overactive immune response in conditions like rheumatoid arthritis and cytokine release syndrome.","oneSentence":"Tocilizumab is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, inhibiting the pro-inflammatory signaling pathway driven by IL-6.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:59.047Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis (moderate to severe)"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Systemic sclerosis-associated interstitial lung disease"},{"name":"Giant cell arteritis"},{"name":"Takayasu arteritis"},{"name":"Cytokine release syndrome (CAR-T cell-induced)"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7889,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RoActemra/Actemra","RoActemra","Actemra"],"phase":"marketed","status":"active","brandName":"tocilizumab [RoActemra/Actemra]","genericName":"tocilizumab [RoActemra/Actemra]","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tocilizumab is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, inhibiting the pro-inflammatory signaling pathway driven by IL-6. Used for Rheumatoid arthritis (moderate to severe), Polyarticular juvenile idiopathic arthritis, Systemic sclerosis-associated interstitial lung disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}